 | |  |
VisEn Medical Announces the Launch of an Industry-First FMT Imaging System and Optical Probe Product Line
CAMBRIDGE, Mass., Sept. 2 /PRNewswire/ - VisEn Medical today announced that it will formally launch its Fluorescence Molecular Tomography ("FMT") system and optical probe product line at the Fourth Annual Meeting of the Society For Molecular Imaging ("SMI"), being held September 7-10 in Cologne, Germany. A pioneer in the field of molecular imaging, VisEn began selling a pre-commercial version of its instrument and its line of optical probe products in the first half of 2005. Underscoring the quantitative power and broad utility of the technology, VisEn's customers, collaborators and company scientists will present a total of 18 abstracts at the SMI meeting, including those on applications in cancer drug testing, bone remodeling and cardiovascular disease.
"We are extremely pleased by the strong customer acceptance of our technology and look forward to expanded commercial shipments and use of our instrument," said Kirtland G. Poss, President and CEO. "Ours is the first optical system to enable truly quantitative, deep tissue, three-dimensional tomographic imaging of fluorescence in animals. In addition, we offer our line of optimized in vivo probes and comprehensive technical support in the chemistry, biology and pharmacology of imaging. We are working with customers to truly apply molecular imaging in their core areas of research and drug development. Our five thought-leading pharmaceutical and academic beta sites and about 20 additional pharmaceutical and academic customers have already begun to use our line of molecular imaging probes for a variety of small animal imaging studies, and the results of some of their work will be on display in Cologne," he added.
5
Abstract #504, "'Smart' Optical Probes in Imaging of Tumor Growth and in Preclinical Drug Testing," by Tsing-Bau Chen and colleagues, evaluated VisEn's instrument and two imaging probes in measuring tumor volume in subcutaneous, metastatic and orthotopic tumor models as compared to measurements using calipers and fluorescence-bioluminescence, thereby providing cross validation between established metrics of disease measurement and novel optical imaging methods for in vivo cancer imaging research.
Abstract #487, "Simultaneous Imaging of Protease Expression and Biodistribution in Her-2/neu Mice Using Dual-Wavelength Fluorescence Molecular Tomography," by Stephen Windsor and colleagues, demonstrates the ability to measure both disease activity and tumor biomarkers simultaneously.
Abstract #527, "Near-Infrared Assessment of Skeletal Turnover by Fluorescence Molecular Tomography," by Kenneth Kozloff and colleagues, demonstrates the use of VisEn's technology for monitoring skeletal turnover in two animal models of bone repair.
Abstract # 270, "In Vivo High-Resolution Near Infrared Imaging of Inflammatory Protease Activity in Experimental Atherosclerosis," by Mathias Nahrendorf and colleagues, illustrates the microscopic level resolution that can be achieved with VisEn's molecular imaging probes.
Founded in 2000 based on technologies developed at the Center for Molecular Imaging Research at the Massachusetts General Hospital, VisEn Medical is developing today's leading molecular imaging product platforms. The Company's proprietary FMT system and optical imaging probe portfolio enable applied imaging at the molecular level. The Company's technology platforms are designed to be fundamentally translatable from animal imaging into the clinic, and its products are targeted to the molecular imaging of important disease states including oncology, bone growth, cardiovascular disease and inflammation. VisEn is headquartered in Woburn, Massachusetts. For further information please visit www.visenmedical.com.
http://www.molecularimaging.org/meeting05/program05.php
Kirtland G. Poss, President and CEO
VisEn Medical, Inc.
781-932-6875 x301
| | |
